摘要
目的:评价阿立哌唑治疗精神分裂症的疗效。方法:选择病程≤3年的80例精神分裂症患者,按入院顺序随机分为阿立哌唑组(40例)和利培酮组(40例)进行6周观察。采用阳性与阴性症状量表(PANSS)评定疗效,用副反应量表(TESS)和锥体外系副反应量表(RSESE)评定不良反应。结果:两药治疗精神分裂症疗效相当。阿立哌唑组的锥体外系反应(EPS)发生率32.5%(13例)明显低于利培酮组55.0%(22例)(P<0.05)。结论:阿立哌唑为一种安全有效和耐受性较好的抗精神病药。
Objective:To evaluate the efficacy of aripiprazole in the treatment of schizophrenia.Method:Eighty hospitalized schizophrenias with a course less than 3 years were randomly divided into two groups,one was treated with aripiprazole(n=40)and the other was treated with resperidone(n=40) for 6 weeks.Both groups were administered with the positive and negative symptoms scale(PANSS),treatment emergent signs and symptoms(TESS) and rating scale for extrapyramidel side effects(RSESE) to evaluate their treatment efficacy and side reaction respectively.Results:The efficacies of both drugs in treatment of schizophrenia were similar,the occurrence of EPS in aripiprazole group was 13 cases(32.5%).It was significantly lower than that of risperidone group(22 cases,55.0%)(P<0.05).Conclusion:Aripiprazole is a safe antipsychotic drug,it has good effect and good compliance.
出处
《临床精神医学杂志》
2006年第2期108-109,共2页
Journal of Clinical Psychiatry
